← Back to patent-cliff list
ION-736
Tier C — Watch / tradeION-736
Ionis Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：FOXP3
Indications (approved)：Neoplasm, Non-small cell lung cancer, Cervical cancer, Melanoma, 三阴性乳腺癌, Renal cell carcinoma, Solid tumour, Oesophageal cancer
Regional status
US
Phase II
2021-12-01
EU
Phase II
2021-12-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ION-736?
Approved indications include: Neoplasm, Non-small cell lung cancer, Cervical cancer, Melanoma, 三阴性乳腺癌, Renal cell carcinoma, Solid tumour, Oesophageal cancer.
When does the ION-736 patent expire?
No public expiry year is available for ION-736 yet; this page updates once verified.
How do I get a quote for ION-736 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06